We are building a pipeline that leverages the broad therapeutic potential of our lead product candidate, LB-102, for the treatment of schizophrenia and other neuropsychiatric diseases.
We are a clinical-stage biopharmaceutical company developing novel therapies for the treatment of neuropsychiatric diseases.
We are evaluating the safety and efficacy of LB-102 in patients with acute schizophrenia.